Home » News » A prospective phase II study of pre-operative chemotherapy then short-course radiotherapy for high risk rectal cancer (COPERNICUS) trial paper publish
26 Oct 2018

Researchers from Queen’s University Belfast and the University of Leeds, as part of a pan-European partnership called the European Cancer Concord (ECC) ®, have won the prestigious 2018 European Health Award.

This award honours initiatives that help tackle some of Europe’s most pressing health challenges.

 

The award-winning project, entitled ‘The European Cancer Patient’s Bill of Rights: A Catalyst for Change and an empowerment tool for cancer patients across Europe’ involves an equal partnership between cancer patients, healthcare professionals and cancer researchers.

Professor Mark Lawler, Vice President of the European Cancer Concord (ECC), today received the award on behalf of ECCO during the opening ceremony of the European Health Forum Gastein, the premier European Health Policy Conference and an official event of the Austrian European Council Presidency. 

25 Jul 2018

Susan Richman from the Leeds Institute of Cancer and Pathology obtained £1120 from the Medical Research Council (MRC)  to fund a stand  at the MRC’s Festival of Medical Research.  The stand titled, ‘So, just what is personalised Medicine?’ was split into three sections, with the first aiming to bust the stigma around bowel cancer screening, incorporating a game and a competition.

SHOW ALL
News
A prospective phase II study of pre-operative chemotherapy then short-course radiotherapy for high risk rectal cancer (COPERNICUS) trial paper publish
28 Aug 2018

Abstract

Background

Neoadjuvant chemotherapy (NAC) allows earlier treatment of rectal cancer micro-metastases but is not standard of care. There are currently no biomarkers predicting long-term progression-free survival (PFS) benefit from NAC.

Patients and methods

In this single arm phase II trial, patients with non-metastatic magnetic resonance imaging (MRI)-defined operable rectal adenocarcinoma at high risk of post-operative metastatic recurrence, received 8 weeks of oxaliplatin/fluorouracil NAC then short-course preoperative radiotherapy (SCPRT) before immediate surgery. Sixteen weeks of post-operative adjuvant chemotherapy (AC) was planned. A pelvic MRI was performed at week 9 immediately post-NAC, before SCPRT. The primary end point was feasibility assessed by completion of protocol treatment up to and including surgery. Secondary endpoints included compliance, toxicity, downstaging efficacy, and PFS.

Results

In total 60 patients were recruited May 2012–June 2014. In total 57 patients completed protocol treatment, meeting the primary endpoint. Compliance with NAC was much better than AC: Comparing NAC vs. AC, the median percentage dose intensity for fluoropyrimidine was 100% vs. 63% and for oxaliplatin 100% vs. 45%. Treatment-related toxicity was acceptable with no treatment-related deaths. Post-NAC MRI showed 44 tumours (73%) were T-downstaged and 22 (37%) had excellent MRI tumour regression grade (mrTRG 1–2). Median follow-up was 27 months with 2-year PFS of 86.2% (10 events). On exploratory analysis, post-NAC mrTRG predicted PFS with no event among those with excellent regression.

Conclusion

The regimen was well tolerated with effective downstaging and encouraging PFS. mrTRG response to NAC may be a new prognostic factor for long-term PFS, but needs validation in larger studies.

 

To read the full paper, click here.

» Back to News
PROJECT
MEMBERS
2015-2020
  • Oxford University King's College London Queen's University Belfast
  • University of Leeds University of Aberdeen Sanger Institute
  • University College London University of Birmingham Partnering to Advance Human Health